Drug

Citalopram

Regulatory activity · MHRA

Emerging researchLate-stage developmentRising momentum

Also known as CeleXA, Citalopram Hydrobromide, Citalopramum.

RxNorm2556 ChEMBLCHEMBL549 ATCN06AB04UNII0DHU5B8D6V

Research papers

Active clinical trials

Regulatory events

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease

Clinical trial2026-03-02Completed · ClinicalTrials.gov

A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Assess Safety and Effectiveness of Liposom in Enhance and Speed up Response With Citalopram in Elderly Patients Suffering From Major Depressive Disorder (MDD)

Clinical trial2025-10-01Primary completion · ClinicalTrials.gov

Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions

Clinical trial2025-07-31Results posted · ClinicalTrials.gov

A Single Dose, Randomized, Placebo Controlled Phase I Study on the Effects of BI 1358894 on Functional MRI Measurements in an Emotional Processing Paradigm in Patients With Major Depressive Disorder

Clinical trial2025-02-25Results posted · ClinicalTrials.gov

The Effects of Citalopram on the Brain's Response to Faces

Clinical trial2025-02-21Results expected Q4 2026 · ClinicalTrials.gov

Prediction of Clinical Response to SSRI Treatment in Bipolar Disorder Using Serotonin 1A Receptor PET Imaging

Clinical trial2024-12-31Results posted · ClinicalTrials.gov

Combining SSRIs and TDCS to Enhance Motor Recovery After Stroke

Clinical trial2024-08-31Primary completion · ClinicalTrials.gov

Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial.

Research2023-10-09Molecular psychiatry

What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapies in real-world depressed patients? A reanalysis of the STAR*D study's patient-level data with fidelity to the original research protocol.

Research2023-07-25BMJ open

Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects.

Research2021-11-22Clinical pharmacology and therapeutics

Drug Safety Update: Citalopram: suspected drug interaction with cocaine; prescribers should consider enquiring about illicit drug use

Regulatory2016-07-18MHRA

Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial.

Research2016-04-01Health technology assessment (Winchester, England)

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Citalopram

Aliases & brands

CeleXACitalopram HydrobromideCitalopramum

RxNorm CUI

2556

ChEMBL ID

CHEMBL549

ATC codes

N06AB04

UNII

0DHU5B8D6V

Regulatory jurisdictions

mhra

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Authorities

MHRA

Total events

mhraMedicines and Healthcare products Regulatory Agency· 1 event

2016-07-18Safety communicationSafety

Drug Safety Update: Citalopram: suspected drug interaction with cocaine; prescribers should consider enquiring about illicit drug use

Evidence ↗

Contains public sector information from the Medicines and Healthcare products Regulatory Agency (MHRA) licensed under the Open Government Licence (OGL v3).

Clinical trials

124 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

124

registered trials across all phases

LATEST COMPLETION 2026

Active studies

Recruiting

Late-stage (III+)

Completed

Discontinued

PHASE DISTRIBUTIONn = 124

Early Phase 14Phase 117Phase 1 / 22Phase 218Phase 2 / 34Phase 314Phase 436Phase N / A29

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Unknown statusPH IVFidia Farmaceutici s.p.a.n=1502025

Assessing Tolerability and Efficacy of Vortioxetine Versus SSRIs in Elderly Patients With Depression: a Pragmatic, Multicenter, Open-label, Parallel-group, Superiority, Randomized Trial

CompletedPH IVAzienda Ospedaliera Universitaria Integrata Veronan=3622023

Effect of Citalopram on Chest Pain in Patients With Functional Chest Pain

TerminatedPH IVAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)n=12022

A Placebo-controlled Trial With Citalopram for the Treatment of Typical Reflux Symptoms in Patients With Reflux Hypersensitivity or Functional Heartburn With Incomplete Proton Pump Inhibitor Response

Unknown statusPH IVUniversitaire Ziekenhuizen KU Leuvenn=1002021

Patient Stratification and Treatment Response Prediction in Neuropharmacotherapy Using Hybrid Positron Emmission Tomography/Magnetic Resconance Imaging (PET/MR)

Unknown statusPH IVMedical University of Viennan=802020

Recent completions

Trials that read out recently, adding to the completed evidence base.

Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease

CompletedPH IIUniversity of Michigann=582026

Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions

CompletedPH IFood and Drug Administration (FDA)n=2412024

Effects of a 14-day Combined Antidepressant and Behavioural Intervention on Emotional Cognition in Healthy Volunteers Experiencing Low Mood

CompletedN/AUniversity of Oxfordn=1342023

Assessing Tolerability and Efficacy of Vortioxetine Versus SSRIs in Elderly Patients With Depression: a Pragmatic, Multicenter, Open-label, Parallel-group, Superiority, Randomized Trial

CompletedPH IVAzienda Ospedaliera Universitaria Integrata Veronan=3622023

The Effects of PF-04995274 on Emotional Processing in Un-medicated Depressed Patients

CompletedPH IUniversity of Oxfordn=902022

A Phase 3, Randomized, Double-Blind Study Comparing the Efficacy and Safety of SAGE-217 Plus an Antidepressant Versus Placebo Plus an Antidepressant in Adults With Major Depressive Disorder

CompletedPH IIIBiogenn=4402021

Research activity

5 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time

20142023

Most influential

Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.

JAMA · 2014 · 368 cites

Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects.

Clinical pharmacology and therapeutics · 2022 · 113 cites

BMJ open · 2023 · 38 cites

Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial.

Molecular psychiatry · 2023 · 38 cites

Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial.

Health technology assessment (Winchester, England) · 2016 · 23 cites

Related drugs

2 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Escitalopram

Studied across the same disease area as Citalopram in the shared literature.

1 shared disease2 shared papers

Psilocybin

Frequently co-studied with Citalopram in the research literature.

1 shared paper

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
Europe PMC — research literature
ClinicalTrials.gov — clinical trials
Regulatory event sources are credited in the Regulatory Timeline above.